Yuhan Joins Immuno-Oncology Wave Via Sorrento JV
This article was originally published in PharmAsia News
One of South Korea's leading pharma firms, Yuhan, is joining the global immuno-oncology wave by setting up a majority-owned joint venture with US-based Sorrento Therapeutics. The JV, Yuhan’s first in R&D, is set to develop and commercialize three of Sorrento's immune checkpoint antibodies.
You may also be interested in...
Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
After probing pharmacokinetic data flaws in the first US Phase III study for its gene therapy Engensis, Korea's Helixmith concludes that these stemmed from clinical operation issues. As a result, it admits a failure to meet the primary endpoint but is still moving forward with new trials given signals of efficacy and safety in an extended study.